Tay Salimullah

Vice President, Head of Global Value & Access, Novartis Gene Therapies  • Novartis

Tay currently is Vice President, Global Head Value & Access at Novartis Gene Therapies, where he oversees the integrated access function to transform rare diseases through gene therapies. He has diverse experience across biopharmaceuticals, consultancy, social sector and private equity. Since joining Novartis in 2013, Tay has led teams across various divisions in Global Pharma, Region Europe, Oncology, Cell & Gene Therapies (part of the original team that lead the first FDA approved cell therapy Kymriah®) and Group Global Health (launching the corporate Africa flagship sickle cell disease program). He was a founding member of Harmony®, the largest real-world data program in hematology in Europe. Earlier in his career, he held a series of commercial positions at Pfizer. In 2009, Tay completed his Global Health Fellowship: in-field healthcare systems experience in Malawi. Tay received his Business Management BSc from the University of Brunel, in the United Kingdom

Also Speaking

Andrés Bratt-Leal

Co-Founder, Senior Vice President, Research and Development • Aspen Neuroscience

Anne Rowzee

Associate Director for Policy, Office of Tissues and Advanced Therapies • FDA

Tessa Rowe

User Experience and Human Factors Engineering • Tensentric

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.